Granix
Legal Notice | GRANIX® (tbo-filgrastim) injection
Granix Indication Expanded to Include Pediatric Patients - MPR
Rx Item-Granix 300MCG 10X1 ML Single Dose Vial -Keep Refrige
Teva - Contract Pharma
Print — Cathy McCartney
These highlights do not include all the information needed to use GRANIX safely and effectively. See full prescribing information for GRANIX.GRANIX® (tbo-filgrastim) injection, for subcutaneous use Initial U.S. Approval: 2012
Updated Indication For Teva's Granix Injection Approved In U.S. - Drug Discovery and Development
A Look at Teva's Dominance in the Biosimilar Space
GRANIX Dosage & Rx Info | Uses, Side Effects
New Drug Product: GRANIX - MPR
ACTAVIS: Teva Announces Updated Indication and Vial Presentation for GRANIX® (tbo-filgrastim) Injection in United States | American Pharmacy News
Market Share by Filgrastim Brand (As a Percentage of Sales Before Rebates) | Download Scientific Diagram
Resources & Support from Teva CORE | GRANIX
US Pharmacist January 2016
Teva bolsters its biosimilar business through $160m Celltrion deal
Teva Pharmaceuticals - pdf download
BUY tbo-filgrastim (GRANIX) 300 ug/.5mL Cephalon, Inc.
Tbo-filgrastim Approved for Chemotherapy-Induced Neutropenia - MPR
GRANIX (TBO-FILGRASTIM) INJECTION Trademark of TEVA Pharmaceutical Industries Limited Serial Number: 86040042 :: Trademarkia Trademarks
Teva's Granix Gets FDA Approval for Expanded Indication
Granix - FDA prescribing information, side effects and uses
